Flerie Valuation Multiples

Flerie Overview

About Flerie

Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations.

Founded

2015

HQ

Employees

7

Website

flerie.com

Sectors

BiopharmaceuticalsBioTech

Financials (FY)

Revenue: —

EBITDA: ($83M)

EV

$189M

Valuation Multiples

Multiples.vc

Start free trial

Flerie Financials

Flerie reported last fiscal year revenue of — and negative EBITDA of ($83M).

In the same fiscal year, Flerie generated ($83M) in EBITDA losses and had net loss of ($83M).

Flerie P&L

In the most recent fiscal year, Flerie reported revenue of — and EBITDA of ($83M).

Flerie expects next 12-month revenue of XXX and NTM EBITDA of XXX

Flerie Stock Performance

Flerie has current market cap of $253M, and enterprise value of $189M.

Flerie's stock price is $3.03.

Flerie Valuation Multiples

Flerie trades at (2.3x) EV/EBITDA.

Flerie Financial Valuation Multiples

As of April 19, 2026, Flerie has market cap of $253M and EV of $189M.

Equity research analysts estimate Flerie's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Flerie has a P/E ratio of (3.1x).

Flerie Margins & Growth Rates

Flerie's revenue in the last fiscal year declined by (100%).

Flerie's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.5M for the same period.

Flerie Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Flerie M&A Activity

Flerie acquired XXX companies to date.

Last acquisition by Flerie was on XXXXXXXX, XXXXX. Flerie acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Flerie Investment Activity

Flerie invested in XXX companies to date.

Flerie made its latest investment on XXXXXXXX, XXXXX. Flerie invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).